FDA Updates Xeloda Labeling to Make DPYD Variant Risks More Explicit
In response to a citizen petition, the FDA has added more specific language about testing patients for DPYD gene variants that place them at risk for severe treatment-related toxicities.
Researchers reported prospective randomized trial data showing non-inferiority of adjuvant treatment guided by minimal residual disease testing.
The 32-gene signature showed potential in predicting South Korean gastric cancer patients' overall survival and response to chemotherapy and immunotherapy.
The firm has launched a validation trial for its in-development QuantiDNA cell-free DNA chemotherapy response assay in late-stage smoking-related cancers.
Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.